SCHEMBL1686750

SCHEMBL1686750

CCCCCCCCc1ccccc1[Si](O)(O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.58
BID P55957 3/20 0.45
MCL1 Q07820 3/20 0.45
BCL2L1 Q07817 2/20 0.45
BAK1 Q16611 2/20 0.45
KAT8 Q9H7Z6 2/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
EP300 Q09472 1/20 0.45
KAT2A Q92830 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT5 Q92993 1/20 0.45
SAE1 Q9UBE0 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
KCNH2 Q12809 1/20 0.44
NR1H2 P55055 1/20 0.44
NR1H3 Q13133 1/20 0.44
ALOX5 P09917 2/20 0.44
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1686485 1.00 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1686933 1.00 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1686748 1.00 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1687032 1.00 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1686456 0.98 LIPG (0.55) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1686813 0.92 LIPG (0.47) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1687091 0.89 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1686411 0.89 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1686606 0.89 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1
SCHEMBL1686687 0.89 LIPG (0.58) LIPGBIDMCL1BCL2L1BAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932330-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-7592402-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-09-22 US disclosed
US-20080319148-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2008-12-25 US disclosed
US-7115539-B2 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
US-20050245701-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2005-11-03 US disclosed
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer AP1M1, PYM1, SEM1 LIPG 4621/4885BID 4824/4885MCL1 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.